SCHEMBL316674

SCHEMBL316674

O=C(C=Cc1ccccc1)CC(=O)C=Cc1ccccc1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HAO1 Q9UJM8 1/20 0.84
ALDH1A1 P00352 2/20 0.70
MAPT P10636 4/20 0.68
KMT2A Q03164 2/20 0.68
KDM4E B2RXH2 1/20 0.68
MEN1 O00255 1/20 0.68
RAB9A P51151 1/20 0.68
KCNH2 Q12809 1/20 0.68
HDAC3 O15379 2/20 0.67
HDAC4 P56524 2/20 0.67
HDAC1 Q13547 2/20 0.67
HDAC2 Q92769 2/20 0.67
HDAC8 Q9BY41 2/20 0.67
HDAC6 Q9UBN7 2/20 0.67
PLIN1 O60240 2/20 0.67
LMNA P02545 2/20 0.67
RECQL P46063 2/20 0.67
PLIN5 Q00G26 2/20 0.67
ABHD5 Q8WTS1 2/20 0.67
TNKS O95271 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3439644 1.00 HAO1 (0.84) HAO1ALDH1A1MAPTKMT2AKDM4E
SCHEMBL7067334 0.94 HAO1 (0.75) HAO1ALDH1A1MAPTKMT2AKDM4E
SCHEMBL10348520 0.94 HAO1 (0.75) HAO1ALDH1A1MAPTKMT2AKDM4E
Dimethylamine SCHEMBL14875132 0.94 HAO1 (0.75) HAO1ALDH1A1MAPTKMT2AKDM4E
SCHEMBL243735 0.94 HAO1 (0.75) HAO1ALDH1A1MAPTKMT2AKDM4E
SCHEMBL15300315 0.92 HAO1 (1.00) HAO1ALDH1A1MAPTKMT2AKDM4E
SCHEMBL15300314 0.92 HAO1 (1.00) HAO1ALDH1A1MAPTKMT2AKDM4E
SCHEMBL1650908 0.90 HAO1 (0.70) HAO1ALDH1A1MAPTKMT2AKDM4E
SCHEMBL11377652 0.90 HAO1 (0.70) HAO1ALDH1A1MAPTKMT2AKDM4E
SCHEMBL1650906 0.90 HAO1 (0.70) HAO1ALDH1A1MAPTKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130102498-A1 COMPOSITIONS AND METHODS FOR DETECTING AMYLOID-BETA-DEGRADING ENZYME ACTIVITY ACADEMIA SINICA (TW) 2013-04-25 US claimed
EP-0239105-B1 PHARMACEUTICAL COMPOSITIONS CONTAINING 5-PHENYL-1,3-DIOXOALKENYL COMPOUNDS G.D. Searle & Co. (US) 1990-05-23 EP claimed
US-4761503-A LEUKOTRIENE BIOSYNTHESIS INHIBITORS CONDENSATION OF BENZALDEHYDE WITH ACETOACETATE COMPOUND G. D. SEARLE & CO. (US) 1988-08-02 US claimed
EP-0239105-A2 Pharmaceutical compositions containing 5-phenyl-1,3-dioxoalkenyl compounds G.D. Searle & Co. (US) 1987-09-30 EP claimed
US-4649157-A ANTIALLERGENS, ANTIINFLAMMATORY G. D. SEARLE & CO. (US) 1987-03-10 US claimed
EP-4717762-A1 CURCUMIN PRODUCING GRAM POSITIVE BACTERIA Universität des Saarlandes, eine Körperschaft des Öffentlichen Rechts (DE) 2026-04-01 EP disclosed
US-11026897-B2 Composition of curcumagalactomannoside and hops extract METAGENICS, INC. (US) 2021-06-08 US disclosed
US-20200046651-A1 METHOD OF TREATING INFLAMMATORY BOWEL DISEASE WHITEHORSE CAPITAL ORIGINATION, LLC, AS AGENT 2020-02-13 US disclosed
WO-2020033796-A1 METHOD OF TREATING INFLAMMATORY BOWEL DISEASE METAGENICS, INC. (US) 2020-02-13 WO disclosed
US-20160039734-A1 THERAPEUTIC CURCUMIN DERIVATIVES STC UNM (US) 2016-02-11 US disclosed
US-9233263-B2 Photoprotector and/or photoimmunoprotector compositions of the skin and their uses INDUSTRIAL FARMACEUTICA CANTABRIA, S.A. (ES) 2016-01-12 US disclosed
US-9187397-B2 Therapeutic curcumin derivatives STC.UNM (US) 2015-11-17 US disclosed
WO-2003035007-A2 CURCUMINOID COMPOSITIONS EXHIBITING SYNERGISTIC INHIBITION OF THE EXPRESSION AND/OR ACTIVITY OF CYCLOOXYGENASE-2 METAPROTEOMICS, LLC (US) 2003-05-01 WO disclosed
WO-2003007975-A1 CURCUMINOID COMPOSITIONS EXHIBITING SYNERGISTIC INHIBITION OF THE EXPRESSION AND/OR ACTIVITY OF CYCLOOXYGENASE-2 METAPROTEOMICS, LLC (US) 2003-01-30 WO disclosed
EP-0210284-B1 1,3-DITHIOL-2-YLIDENE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 1992-08-19 EP disclosed
US-4761503-A LEUKOTRIENE BIOSYNTHESIS INHIBITORS CONDENSATION OF BENZALDEHYDE WITH ACETOACETATE COMPOUND G. D. SEARLE & CO. (US) 1988-08-02 US disclosed
EP-0239105-A2 Pharmaceutical compositions containing 5-phenyl-1,3-dioxoalkenyl compounds G.D. Searle & Co. (US) 1987-09-30 EP disclosed
US-4668799-A Anti-hepatitis and anti-cirrhotic 1,3-dithiol-2-ylidene derivatives, and pharmaceutical compositions therefor BANYU PHARMACEUTICAL CO., LTD. (JP) 1987-05-26 US disclosed
US-4649157-A ANTIALLERGENS, ANTIINFLAMMATORY G. D. SEARLE & CO. (US) 1987-03-10 US disclosed
EP-0210284-A1 1,3-Dithiol-2-ylidene derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 1987-02-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160039734-A1 THERAPEUTIC CURCUMIN DERIVATIVES FABP2, GLS2, FABP1 HAO1 3822/4885ALDH1A1 670/4885MAPT 448/4885
US-11026897-B2 Composition of curcumagalactomannoside and hops extract HMGB1, CHIT1, NOD2 HAO1 1816/4885ALDH1A1 4598/4885MAPT 1152/4885
US-20200046651-A1 METHOD OF TREATING INFLAMMATORY BOWEL DISEASE NOD2, NLRP1, NOD1 HAO1 1452/4885ALDH1A1 4630/4885MAPT 1167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.